The need for comparative data in spondyloarthritis

Autor: Michael Rissler, Frank Behrens, Kamel Chaouche-Teyara, Chiara Perella, Georg Schett, Salvatore D'Angelo, Xenofon Baraliakos, Kurt de Vlam, Bruce Kirkham, Mikkel Østergaard, Ernest Choy
Přispěvatelé: Publica
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
medicine.medical_specialty
lcsh:Diseases of the musculoskeletal system
Spondyloarthropathy
Network Meta-Analysis
Disease
EARLY PSORIATIC-ARTHRITIS
Dactylitis
03 medical and health sciences
Psoriatic arthritis
0302 clinical medicine
Clinical trials
Rheumatology
INFLAMMATION
Medizinische Fakultät
SCORING METHODS
Outcome Assessment
Health Care
Spondylarthritis
INFLIXIMAB
Protocol
Humans
Medicine
Biological therapy
ddc:610
Intensive care medicine
Biosimilar Pharmaceuticals
Randomized Controlled Trials as Topic
030203 arthritis & rheumatology
Science & Technology
business.industry
Enthesitis
Antibodies
Monoclonal
ANKYLOSING-SPONDYLITIS
Biosimilar
Evidence-based medicine
medicine.disease
Clinical trial
Radiography
SECUKINUMAB
030104 developmental biology
RELIABILITY
medicine.symptom
lcsh:RC925-935
business
Life Sciences & Biomedicine
ADALIMUMAB
Zdroj: Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-6 (2019)
Choy, E, Baraliakos, X, Behrens, F, D'Angelo, S, De Vlam, K, Kirkham, B W, Østergaard, M, Schett, G A, Rissler, M, Chaouche-Teyara, K & Perella, C 2019, ' The need for comparative data in spondyloarthritis ', Arthritis Research and Therapy, vol. 21, 32 . https://doi.org/10.1186/s13075-019-1812-3
Arthritis Research & Therapy
ISSN: 1478-6354
DOI: 10.1186/s13075-019-1812-3
Popis: Spondyloarthritis comprises a group of inflammatory diseases, characterised by inflammation within axial joints and/or peripheral arthritis, enthesitis and dactylitis. An increasing number of biologic treatments, including biosimilars, are available for the treatment of spondyloarthritis. Although there are a growing number of randomised controlled trials assessing treatments in spondyloarthritis, there is a paucity of data from head-to-head studies. Comparative data are required so that clinicians and payers have the level of evidence required to inform clinical decision-making and health economic assessments. In the absence of head-to-head studies, statistical methods such as network meta-analyses and matching-adjusted indirect comparisons (MAICs) are used for assessing comparative effectiveness.Network meta-analysis can be used to compare treatments for trials using a common comparator (e.g. placebo); however, for those without a common comparator or where considerable heterogeneity exists between the study populations, a MAIC that controls for differences in study design and baseline patient characteristics may be used. MAICs, unlike network meta-analyses, are of value for longer-term comparisons beyond the placebo-controlled phase of clinical trials, which is important for chronic diseases requiring long-term treatment, like spondyloarthritis. At present, there are a number of limitations that restrict the effectiveness of MAIC, such as the poor availability of individual patient-level data from trials, which results in patient-level data from one trial being compared with published whole-population data from another. Despite these limitations, drug reimbursement agencies are increasingly accepting MAIC as a means of comparative effectiveness and greater methodological guidance is needed.This report highlights a number of challenges that are specific to conducting comparative studies like MAIC in spondyloarthritis, including disease heterogeneity, the paucity of biomarkers and the duration of studies required for radiographic endpoints in this slow-progressing disease. ispartof: ARTHRITIS RESEARCH & THERAPY vol:21 issue:1 ispartof: location:England status: published
Databáze: OpenAIRE
Externí odkaz: